CY1108021T1 - Αναστολη αρωματασης για ενισχυση του ρυθμου εμφυτευσης - Google Patents

Αναστολη αρωματασης για ενισχυση του ρυθμου εμφυτευσης

Info

Publication number
CY1108021T1
CY1108021T1 CY20071100965T CY071100965T CY1108021T1 CY 1108021 T1 CY1108021 T1 CY 1108021T1 CY 20071100965 T CY20071100965 T CY 20071100965T CY 071100965 T CY071100965 T CY 071100965T CY 1108021 T1 CY1108021 T1 CY 1108021T1
Authority
CY
Cyprus
Prior art keywords
flavors
boost
suspension
aromatase inhibitor
implantation rate
Prior art date
Application number
CY20071100965T
Other languages
English (en)
Inventor
Robert F Casper
Mohamed F M Mitwally
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of CY1108021T1 publication Critical patent/CY1108021T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

Η χρήση ενός τουλάχιστον αναστολέα αρωματάσης στην παραγωγή φαρμάκου για βελτίωση των ρυθμών εμφύτευσης και εγκυμοσύνης για θήλυ που υποβάλλεται σε υποβοηθούμενη θεραπεία αναπαραγωγής, η οποία περιλαμβάνει μία ή περισσότερες ημερήσιες δόσεις αναστολέα αρωματάσης (ΑΙ) για χορήγηση κατά τη διάρκεια υποβοηθούμενων κύκλων αναπαραγωγής ή κύκλων ωοθηκικής διέγερσης, όπου οι δόσεις του ΑΙ (αναστολέα αρωματάσης) επιλέγονται από ποσότητες αποτελεσματικές για μείωση των επιπέδων οιστραδιόλης στον ορό. Αποκαλύπτονται επίσης σχετικά φαρμακευτικά παρασκευάσματα και συσκευασίες.
CY20071100965T 2001-04-17 2007-07-19 Αναστολη αρωματασης για ενισχυση του ρυθμου εμφυτευσης CY1108021T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28417801P 2001-04-17 2001-04-17
EP02717917A EP1381431B1 (en) 2001-04-17 2002-04-17 Aromatase inhibition to enhance implantation rate

Publications (1)

Publication Number Publication Date
CY1108021T1 true CY1108021T1 (el) 2013-09-04

Family

ID=23089175

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100965T CY1108021T1 (el) 2001-04-17 2007-07-19 Αναστολη αρωματασης για ενισχυση του ρυθμου εμφυτευσης

Country Status (33)

Country Link
US (1) US7846957B2 (el)
EP (1) EP1381431B1 (el)
JP (1) JP2004526764A (el)
KR (1) KR20040012751A (el)
CN (1) CN100377710C (el)
AR (1) AR034310A1 (el)
AT (1) ATE363906T1 (el)
AU (1) AU2002249041B2 (el)
BG (1) BG108316A (el)
BR (1) BR0208968A (el)
CA (1) CA2444932A1 (el)
CY (1) CY1108021T1 (el)
CZ (1) CZ299735B6 (el)
DE (1) DE60220516T2 (el)
DK (1) DK1381431T3 (el)
EA (1) EA010354B1 (el)
EE (1) EE200300512A (el)
ES (1) ES2283541T3 (el)
HK (1) HK1067987A1 (el)
HR (1) HRP20030838A2 (el)
HU (1) HUP0303795A2 (el)
IL (2) IL158395A0 (el)
MX (1) MXPA03009446A (el)
NO (1) NO20034245L (el)
NZ (1) NZ528501A (el)
PL (1) PL366554A1 (el)
PT (1) PT1381431E (el)
SI (1) SI1381431T1 (el)
SK (1) SK14252003A3 (el)
UA (1) UA79591C2 (el)
WO (1) WO2002083240A1 (el)
YU (1) YU81303A (el)
ZA (1) ZA200307514B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312393A (pt) * 2002-07-02 2005-04-12 Pharmacia & Upjohn Co Llc Tratamento de infertilidade com exemestano
CA2837494C (en) 2010-05-20 2019-12-31 University Of Saskatchewan Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
WO2012127501A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
SG2014012132A (en) 2011-09-08 2014-06-27 Novartis Ag Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
US10004723B2 (en) 2013-04-19 2018-06-26 University Of Saskatchewan Aromatase inhibitor-releasing intravaginal device
CN107648594A (zh) * 2017-11-08 2018-02-02 广州市桐晖药业有限公司 枸橼酸氯米芬胶囊及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289762A (en) * 1980-06-27 1981-09-15 Merrell Dow Pharmaceuticals Inc. 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4845227A (en) * 1984-06-18 1989-07-04 Eli Lilly And Company Aromatase inhibitors from azoles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
DE4330237C2 (de) * 1993-09-02 1995-11-30 Schering Ag 1-Methylsubstituierte Androsta-1,4-dien-3,17-dione, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
AU1793397A (en) 1996-03-29 1997-10-22 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite
US6015789A (en) * 1996-04-30 2000-01-18 Takeda Chemical Industries, Ltd. Combined use of GnRH agonist and antagonist
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE302018T1 (de) * 1997-06-20 2005-09-15 Akzo Nobel Nv Gonadotropin releasing hormon antagonist
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
UA79591C2 (en) 2007-07-10
AR034310A1 (es) 2004-02-18
EP1381431B1 (en) 2007-06-06
NO20034245D0 (no) 2003-09-23
HRP20030838A2 (en) 2005-08-31
PL366554A1 (en) 2005-02-07
EA010354B1 (ru) 2008-08-29
BR0208968A (pt) 2004-04-27
HK1067987A1 (en) 2005-04-22
ZA200307514B (en) 2004-09-27
ES2283541T3 (es) 2007-11-01
MXPA03009446A (es) 2004-05-24
WO2002083240A9 (en) 2004-05-06
CN1549734A (zh) 2004-11-24
JP2004526764A (ja) 2004-09-02
WO2002083240A1 (en) 2002-10-24
SI1381431T1 (sl) 2007-08-31
ATE363906T1 (de) 2007-06-15
IL158395A0 (en) 2004-05-12
YU81303A (sh) 2006-05-25
CN100377710C (zh) 2008-04-02
EP1381431A1 (en) 2004-01-21
HUP0303795A2 (hu) 2004-03-29
EA200301129A1 (ru) 2004-04-29
BG108316A (bg) 2004-12-30
DE60220516T2 (de) 2007-10-11
EE200300512A (et) 2004-02-16
NZ528501A (en) 2008-04-30
US20040204393A1 (en) 2004-10-14
CZ299735B6 (cs) 2008-11-05
AU2002249041B2 (en) 2007-07-12
NO20034245L (no) 2003-12-15
SK14252003A3 (sk) 2004-03-02
IL158395A (en) 2009-06-15
DE60220516D1 (de) 2007-07-19
KR20040012751A (ko) 2004-02-11
DK1381431T3 (da) 2007-10-08
CA2444932A1 (en) 2002-10-24
US7846957B2 (en) 2010-12-07
CZ20033108A3 (en) 2004-06-16
PT1381431E (pt) 2007-07-03

Similar Documents

Publication Publication Date Title
CY1108021T1 (el) Αναστολη αρωματασης για ενισχυση του ρυθμου εμφυτευσης
NO20024586D0 (no) Metode og preparater for å forhindre hormoninduserte bivirkninger
MY141584A (en) Pharmaceutical uses of bisphosphonates
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
GEP20063773B (en) Steroid Sulphatase Inhibitors
AP1760A (en) Platinum derivative pharmaceutical formulations.
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
DE60019334D1 (de) Antivirale arznei
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
HK1068606A1 (en) Novel aminobenzoephenones
HUP0301460A2 (hu) Antiprogresztinek használata hormonfüggő betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállításához
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
CY1108648T1 (el) Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
SE9902597D0 (sv) New use
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
BR0208955A (pt) Inibidores de aromatase para tratamento de infertilidade
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
WO2002074315A8 (de) Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
EP1759734A3 (en) Aromatase inhibition to enhance assisted reproduction